Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Jerusalem Pharmaceutical CoXPAE:JPH 82 Net Margin % is 19.10% as of Mar. 2026, which is 22% above its 10-year median of 15.63. GuruFocus rates XPAE:JPH with a GF Score™ of 82/100 and a GF Value™ of $2.41 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 961 Drug Manufacturers companies, Jerusalem Pharmaceutical Co ranks better than 87.51% on this metric.
The historical rank and industry rank for Jerusalem Pharmaceutical Co's Net Margin % or its related term are showing as below:
XPAE:JPH'
s Net Margin % Range Over the Past 10 Years
Min: 10.23 Med: 15.63 Max: 20.8
Current: 20.37
XPAE:JPH's Net Margin % is ranked better than 87.51% of 961
companies
in the Drug Manufacturers industry
Industry Median: 5.54
vs XPAE:JPH: 20.37
Jerusalem Pharmaceutical Co (XPAE:JPH) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Jerusalem Pharmaceutical Co Net Margin % Related Terms
Jerusalem Pharmaceutical Co Net Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XPAE:JPH vs ZTS, UTHR, VTRS: Net Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Jerusalem Pharmaceutical Co's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Jerusalem Pharmaceutical Co Net Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Jerusalem Pharmaceutical Co's Net Margin % distribution charts can be found below:
* The bar in red indicates where Jerusalem Pharmaceutical Co's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Jerusalem Pharmaceutical Co (XPAE:JPH) has a Net Margin % of 19.10% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on Jerusalem Pharmaceutical Co and its competitors. This is 22% above median its historical median of 15.63. Over the past decade, Jerusalem Pharmaceutical Co's Net Margin % has ranged from 10.23 to 20.80. According to the industry distribution chart, Jerusalem Pharmaceutical Co ranks #120 out of 961 companies in the Drug Manufacturers industry, placing it in the top 12.5%.
Is Jerusalem Pharmaceutical Co's Net Margin % too high?
Jerusalem Pharmaceutical Co's current Net Margin % of 19.10% is 22% above median its 10-year median of 15.63. Over the past 10 years, this metric has ranged from a low of 10.23 to a high of 20.80. The Drug Manufacturers industry median Net Margin % is 5.54. Jerusalem Pharmaceutical Co's value of 19.10% is 244.8% above this industry median. Based on the distribution chart, Jerusalem Pharmaceutical Co ranks #120 out of 961 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Jerusalem Pharmaceutical Co has a GF Score™ of 82/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Jerusalem Pharmaceutical Co's Net Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Jerusalem Pharmaceutical Co ranks #120 out of 961 companies for Net Margin %. This places Jerusalem Pharmaceutical Co in the top 13% of its industry — outperforming the majority of peers. The industry median Net Margin % is 5.54. Jerusalem Pharmaceutical Co's value of 19.10% is 244.8% above this benchmark. Historically, Jerusalem Pharmaceutical Co's own Net Margin % has ranged from 10.23 to 20.80 over the past decade. While the company's 10-year median is 15.63 vs. the industry median of 5.54, Jerusalem Pharmaceutical Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Drug Manufacturers company?
The median Net Margin % among Drug Manufacturers companies is 5.54, based on 961 companies in the industry. Companies in the top quartile (top 25%) have a Net Margin % significantly above this median, while those in the bottom quartile fall well below. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Jerusalem Pharmaceutical Co's current Net Margin % of 19.10% is 244.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Jerusalem Pharmaceutical Co and its competitors. For the Drug Manufacturers industry, the median Net Margin % is 5.54 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Jerusalem Pharmaceutical Co's current Net Margin % is 19.10%, which is 22% above median its own 10-year median of 15.63. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jerusalem Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Jerusalem Pharmaceutical Co (XPAE:JPH) is currently considered Significantly Overvalued. The stock's GF Value™ is $2.41, compared to a current price of $3.57 — trading 48.1% above its estimated fair value. The current Net Margin % is 19.10%, which is 22% above median its 10-year median of 15.63 and 244.8% above the Drug Manufacturers industry median of 5.54. Jerusalem Pharmaceutical Co's overall GF Score™ is 82/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Jerusalem Pharmaceutical Co (XPAE:JPH), the current Net Margin % is 19.10% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Jerusalem Pharmaceutical Co (XPAE:JPH) Overvalued in 2026?
Based on GuruFocus' analysis, Jerusalem Pharmaceutical Co stock appears to be overvalued.
The current stock price of $3.57 is trading 48.1% above its estimated GF Value™ of $2.41.
GuruFocus considers Jerusalem Pharmaceutical Co to be Significantly Overvalued.
Key valuation signals for XPAE:JPH:
Net Margin %: 19.10% (22% above median its 10-year median of 15.63)
GF Value™: $2.41 vs. price of $3.57 (48.1% above fair value)
Industry Position: 244.8% above the Drug Manufacturers median (#120 of 961)
No single metric tells the full story. See the XPAE:JPH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Jerusalem Pharmaceutical Co is engaged in developing, manufacturing and marketing of human pharmaceuticals products. It also produces detergent, cosmetic, personal and home care products, veterinary and agricultural products. The company operates in Jordan, Algeria, the Middle East, and North Africa Region. Its product portfolio contains more than 300 pharmaceutical products in various dosage forms including tablets, capsules, sterile injectables, powders for suspensions, suspensions, syrups, powders, suppositories, ovules, creams, ointments, as well as ear and nose drops and solutions.
82GF Score
Get the complete analysis for XPAE:JPH
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XPAE:JPH has been successfully added to your 
